ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Compounded T raises T levels to Premenopausal Ranges in Postmenopausal Women with HSDD
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 179252" data-attributes="member: 13851"><p><span style="font-size: 26px"><strong><span style="color: rgb(184, 49, 47)">MON-LB002</span> Compounded Testosterone Preparations Raise Testosterone Levels to Premenopausal Ranges in Postmenopausal Women With Hypo-Sexual Desire Disorder (HSDD)</strong></span></p><p></p><p><a href="https://www.excelmale.com/forum/javascript%3A;" target="_blank">Beatriz Rodriguez Olson, MD FACP</a></p><p></p><p></p><p></p><p></p><p><span style="font-size: 22px"><strong>Abstract</strong></span></p><p></p><p></p><p><strong>Introduction</strong></p><p></p><p><em>Testosterone (T) in women declines with age. T levels cannot differentiate women with or without HSDD. <strong><span style="color: rgb(184, 49, 47)"><em>T therapy approximating upper physiologic premenopausal levels improves all domains of sexual desire, and libido, and decreases sexual distress.</em></span></strong> <span style="color: rgb(44, 130, 201)"><strong><em>As of 2020, there are no FDA-approved T preparations for women. Male preparations of T are frequently used off-label to treat HSDD.</em></strong></span> <span style="color: rgb(184, 49, 47)"><strong><em>No peer-reviewed data exists on T levels achieved with compounded testosterone preparations from a single reliable source. This study assesses the efficacy of four compounded T preparations to raise T levels, using typically recommended doses.</em></strong></span> T was obtained from a single Pharmacy Compounding Accreditation Board (PCAB)-certified pharmacy.</em></p><p></p><p></p><p><strong>Methods</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Twenty-six matched baseline and post-treatment T levels were obtained as part of standard care for post-menopausal women (age 61±6 years) 3 months after being prescribed T for HSDD. </em></span></strong><em><span style="color: rgb(44, 130, 201)"><strong>T was obtained from the Women’s International Pharmacy. T doses were 0.5-2.0 mg/day, 6 days a week, using 4 methods of administration based on the patient’s preferences:</strong></span><strong> <span style="color: rgb(0, 0, 0)">1) </span><span style="color: rgb(184, 49, 47)">cutaneous cream to the skin (CS) behind the knees (n=12); </span><span style="color: rgb(0, 0, 0)">2)</span><span style="color: rgb(184, 49, 47)"> intravaginal suppositories (IVS) (n=5);</span><span style="color: rgb(0, 0, 0)"> 3) </span><span style="color: rgb(184, 49, 47)">intravaginal oil-capsules (IVoil-C) (n=7); and </span><span style="color: rgb(0, 0, 0)">4)</span><span style="color: rgb(184, 49, 47)"> vulvar cream (VC) (n=2).</span></strong> The mean<span style="color: rgb(0, 0, 0)"><strong> T dose was 1.5±0.6 mg/day.</strong></span> All patients gave consent for use of their T data and were compliant with treatment for a week prior to testing. <span style="color: rgb(0, 0, 0)"><strong><u>Measures of total T were performed by MS/LC, and of free T by equilibrium dialysis.</u></strong></span> <span style="color: rgb(0, 0, 0)"><strong>Normal ranges for total T is 15-70 ng/dl and free T is 0.5-6.5 pg/ml. </strong></span>Paired T-tests comparisons between baseline and treatment values were done within each group where n was sufficient. (*p<0.05, **p<0.01).</em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em><strong><span style="color: rgb(184, 49, 47)">Baseline and treatment total T (ng/dl) were 18.3±3.6 and 55.3±5.2** for CS</span></strong></em>, <strong><em><span style="color: rgb(26, 188, 156)">19.8±4.3 and 56.6±15.9 for IVS (p=NS),</span></em></strong> <span style="color: rgb(147, 101, 184)"><strong><em>23.0±3.2 and 89.2±23* for IVoil-C,</em></strong></span> <span style="color: rgb(44, 130, 201)"><em><strong>and 25.0±3.0 and 182±47 for VC.</strong></em></span> <span style="color: rgb(184, 49, 47)"><strong><em>Baseline and treatment-free T (pg/ml) were 1.18±0.26 and 4.16±0.6** for CS,</em></strong></span> <em><strong><span style="color: rgb(26, 188, 156)">1.12±0.2 and 3.46±1.3 for IVS,</span></strong></em> <em><strong><span style="color: rgb(147, 101, 184)">1.60±0.2 and 5.95±1.2* for IVoil-C,</span></strong></em> <span style="color: rgb(44, 130, 201)"><strong><em>and 1.36±0.4 and 9.45±1.2 for VC.</em></strong></span> <strong><em><span style="color: rgb(0, 0, 0)">Testosterone administration by </span></em><span style="color: rgb(0, 0, 0)"><em>CS</em> </span><em><span style="color: rgb(0, 0, 0)">or IVoil-C significantly increased testosterone levels to the upper normal premenopausal range in women with HSDD.</span></em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Conclusion</strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong><em>Treatment of HSDD in postmenopausal women with compounded T via CS or IVoil-C, at doses of 0.5-2.0 mg, effectively raises T levels to the upper premenopausal range. </em></strong></span><em>Vaginal oil capsules may be particularly useful in avoiding accidental hormone contact with other household members. </em><strong><span style="color: rgb(44, 130, 201)"><em>An FDA-approved form of T replacement would be a welcome treatment for women with HSDD.</em></span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 179252, member: 13851"] [SIZE=26px][B][COLOR=rgb(184, 49, 47)]MON-LB002[/COLOR] Compounded Testosterone Preparations Raise Testosterone Levels to Premenopausal Ranges in Postmenopausal Women With Hypo-Sexual Desire Disorder (HSDD)[/B][/SIZE] [URL='https://www.excelmale.com/forum/javascript%3A;']Beatriz Rodriguez Olson, MD FACP[/URL] [SIZE=22px][B]Abstract[/B][/SIZE] [B]Introduction[/B] [I]Testosterone (T) in women declines with age. T levels cannot differentiate women with or without HSDD. [B][COLOR=rgb(184, 49, 47)][I]T therapy approximating upper physiologic premenopausal levels improves all domains of sexual desire, and libido, and decreases sexual distress.[/I][/COLOR][/B] [COLOR=rgb(44, 130, 201)][B][I]As of 2020, there are no FDA-approved T preparations for women. Male preparations of T are frequently used off-label to treat HSDD.[/I][/B][/COLOR] [COLOR=rgb(184, 49, 47)][B][I]No peer-reviewed data exists on T levels achieved with compounded testosterone preparations from a single reliable source. This study assesses the efficacy of four compounded T preparations to raise T levels, using typically recommended doses.[/I][/B][/COLOR] T was obtained from a single Pharmacy Compounding Accreditation Board (PCAB)-certified pharmacy.[/I] [B]Methods [COLOR=rgb(184, 49, 47)][I]Twenty-six matched baseline and post-treatment T levels were obtained as part of standard care for post-menopausal women (age 61±6 years) 3 months after being prescribed T for HSDD. [/I][/COLOR][/B][I][COLOR=rgb(44, 130, 201)][B]T was obtained from the Women’s International Pharmacy. T doses were 0.5-2.0 mg/day, 6 days a week, using 4 methods of administration based on the patient’s preferences:[/B][/COLOR][B] [COLOR=rgb(0, 0, 0)]1) [/COLOR][COLOR=rgb(184, 49, 47)]cutaneous cream to the skin (CS) behind the knees (n=12); [/COLOR][COLOR=rgb(0, 0, 0)]2)[/COLOR][COLOR=rgb(184, 49, 47)] intravaginal suppositories (IVS) (n=5);[/COLOR][COLOR=rgb(0, 0, 0)] 3) [/COLOR][COLOR=rgb(184, 49, 47)]intravaginal oil-capsules (IVoil-C) (n=7); and [/COLOR][COLOR=rgb(0, 0, 0)]4)[/COLOR][COLOR=rgb(184, 49, 47)] vulvar cream (VC) (n=2).[/COLOR][/B] The mean[COLOR=rgb(0, 0, 0)][B] T dose was 1.5±0.6 mg/day.[/B][/COLOR] All patients gave consent for use of their T data and were compliant with treatment for a week prior to testing. [COLOR=rgb(0, 0, 0)][B][U]Measures of total T were performed by MS/LC, and of free T by equilibrium dialysis.[/U][/B][/COLOR] [COLOR=rgb(0, 0, 0)][B]Normal ranges for total T is 15-70 ng/dl and free T is 0.5-6.5 pg/ml. [/B][/COLOR]Paired T-tests comparisons between baseline and treatment values were done within each group where n was sufficient. (*p<0.05, **p<0.01).[/I] [B]Results[/B] [I][B][COLOR=rgb(184, 49, 47)]Baseline and treatment total T (ng/dl) were 18.3±3.6 and 55.3±5.2** for CS[/COLOR][/B][/I], [B][I][COLOR=rgb(26, 188, 156)]19.8±4.3 and 56.6±15.9 for IVS (p=NS),[/COLOR][/I][/B] [COLOR=rgb(147, 101, 184)][B][I]23.0±3.2 and 89.2±23* for IVoil-C,[/I][/B][/COLOR] [COLOR=rgb(44, 130, 201)][I][B]and 25.0±3.0 and 182±47 for VC.[/B][/I][/COLOR] [COLOR=rgb(184, 49, 47)][B][I]Baseline and treatment-free T (pg/ml) were 1.18±0.26 and 4.16±0.6** for CS,[/I][/B][/COLOR] [I][B][COLOR=rgb(26, 188, 156)]1.12±0.2 and 3.46±1.3 for IVS,[/COLOR][/B][/I] [I][B][COLOR=rgb(147, 101, 184)]1.60±0.2 and 5.95±1.2* for IVoil-C,[/COLOR][/B][/I] [COLOR=rgb(44, 130, 201)][B][I]and 1.36±0.4 and 9.45±1.2 for VC.[/I][/B][/COLOR] [B][I][COLOR=rgb(0, 0, 0)]Testosterone administration by [/COLOR][/I][COLOR=rgb(0, 0, 0)][I]CS[/I] [/COLOR][I][COLOR=rgb(0, 0, 0)]or IVoil-C significantly increased testosterone levels to the upper normal premenopausal range in women with HSDD.[/COLOR][/I] Conclusion[/B] [COLOR=rgb(184, 49, 47)][B][I]Treatment of HSDD in postmenopausal women with compounded T via CS or IVoil-C, at doses of 0.5-2.0 mg, effectively raises T levels to the upper premenopausal range. [/I][/B][/COLOR][I]Vaginal oil capsules may be particularly useful in avoiding accidental hormone contact with other household members. [/I][B][COLOR=rgb(44, 130, 201)][I]An FDA-approved form of T replacement would be a welcome treatment for women with HSDD.[/I][/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Compounded T raises T levels to Premenopausal Ranges in Postmenopausal Women with HSDD
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top